Reforgene named a 2022 potential unicorn enterprise of Huangpu District and Guangzhou Development District
Recently, the Science and Technology Bureau of Huangpu District, Guangzhou, announced the 2022 list of unicorn (potential unicorn) enterprises of Huangpu District and Guangzhou Development District. Reforgene was successfully selected as a potential unicorn enterprise, proving that it has received high recognition from the competent authorities in terms of innovation capability, development potential, industry position and development speed.
Unicorn (potential unicorn) enterprises are typical representatives of the new economy, playing an important role in opening up new fields and new tracks, shaping new development drivers and advantages, and promoting high-quality regional development. This 2022 unicorn (potential unicorn) enterprise list of Huangpu District and Guangzhou Development District was selected from thousands of enterprises through multi-dimensional consideration, choosing the outstanding representatives with the strongest comprehensive strength, aiming to strengthen precise services for unicorn enterprises and promote their high-quality development.
Reforgene stood out in this selection, fully demonstrating its strong development potential. As a representative enterprise in China's gene editing drug innovation field, Reforgene, since its establishment in 2019, has always been driven by gene editing technology and dedicated to the birth of novel medicines, with pipeline programs in hematology, ophthalmology, liver and central nervous system fields. At present, its independently developed transfusion-dependent beta-thalassemia gene editing medicine RM001 has achieved leading excellent efficacy, with Phase I clinical trials nearing completion and Phase II clinical trials planned for 2024. This achievement of Reforgene demonstrates its unique competitiveness in the gene editing field and brings new hope and possibilities to the medical community.
Winning the honor of "Potential Unicorn Enterprise" is not only recognition and encouragement from Huangpu District and Guangzhou Development District, but also a weighty social responsibility. "The road ahead is long and far; I will search high and low." Reforgene is always on the road, upholding the philosophy of "Innovation for Life", based on revolutionary gene technology, adhering to independent R&D and innovation, and providing accessible, curative medicines for patients with serious diseases in China and around the world.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.